WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

Authors

Miwako Kobayashi, Centers for Disease Control and Prevention
Stephanie J. Schrag, Centers for Disease Control and Prevention
Mark R. Alderson, Center for Vaccine Innovation and Access
Shabir A. Madhi, University of the Witwatersrand, Johannesburg
Carol J. Baker, Baylor College of Medicine
Ajoke Sobanjo-ter Meulen, Bill & Melinda Gates Foundation
David C. Kaslow, Center for Vaccine Innovation and Access
Peter G. Smith, London School of Hygiene & Tropical Medicine
Vasee S. Moorthy, World Health Organization
Johan Vekemans, World Health Organization

Date of this Version

2016

Citation

Vaccine xxx (2016) xxx–xxx

Comments

Copyright 2016 The Authors. This is an open access article under the CC BY license

Abstract

Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90 days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.